The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Nektar Therapeutics shares valued at $7,177 were sold by Zalevsky Jonathan on May 19 ’25. At $0.67 per share, Zalevsky Jonathan sold 10,712 shares. The insider’s holdings dropped to 305,892 shares worth approximately $8.16 million following the completion of this transaction.
Also, Wilson Mark Andrew sold 9,996 shares, netting a total of over 6,697 in proceeds. Following the sale of shares at $0.67 each, the insider now holds 314,296 shares.
Before that, ROBIN HOWARD W had sold 23,208 shares from its account. In a trade valued at $15,549, the President & CEO traded Nektar Therapeutics shares for $0.67 each. Upon closing the transaction, the insider’s holdings decreased to 23,208 shares, worth approximately $28.37 million.
As published in a research note from H.C. Wainwright on June 24, 2025, Nektar Therapeutics [NKTR] has been retained to a Buy and the price target has been revised to $120. Analysts at BTIG Research resumed the stock at ‘”a Buy”‘ outlook in a report released in late June. As of April 11, 2025, Jefferies has increased its “Hold” rating to a “Buy” for NKTR. Earlier on March 14, 2025, Oppenheimer upgraded its rating. Their new recommendation was “an Outperform” for NKTR stock which previously was a “a Perform”.
Analyzing NKTR Stock Performance
On last trading session,, Nektar Therapeutics [NASDAQ: NKTR] rose 10.48% to $26.67. The stock’s lowest price that day was $23.445, but it reached a high of $26.8904 in the same session. During the last five days, there has been a surge of approximately 6.25%. Over the course of the year, Nektar Therapeutics shares have jumped approximately 27.00%.
Support And Resistance Levels for Nektar Therapeutics (NKTR)
RSI (Relative Strength Index) is 67.57 on the 14-day chart, showing neutral technical sentiment.
Is Nektar Therapeutics subject to short interest?
Stocks of Nektar Therapeutics saw a sharp steep in short interest on 2025-06-13 dropping by -0.11 million shares to 0.6 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 0.71 million shares. A decline of -19.3% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 2.36 of the overall float, the days-to-cover ratio (short ratio) decline to 2.36.
Which companies own the most shares of Nektar Therapeutics (NKTR)?
In terms of Nektar Therapeutics share price expectations, FactSet research, analysts set an average price target of 18.5 in the next 12 months, down nearly -23.36% from the previous closing price of $24.14. Analysts anticipate Nektar Therapeutics stock to reach 24 by 2025, with the lowest price target being 6. In spite of this, 3 analysts ranked Nektar Therapeutics stock as Buy at the end of 2025. On January 08, 2025, B. Riley Securities assigned a price target of “a Buy” to the stock and initiated coverage with a $4.
